Preclinical development of OR-449, a novel targeted therapy for adrenocortical cancer

$13.06M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Orphagen Pharmaceuticals
Country	United States
Start Date	Jul 05, 2021
End Date	Dec 31, 2022
Duration	544 days
Number of Grantees	1
Roles	Principal Investigator
Data Source	NIH (US)
Grant ID	`10326044`

Grant Description

ABSTRACT Adrenocortical carcinoma (ACC) is a rare, aggressive cancer. The majority of cases are metastatic or locally advanced at diagnosis with a dismal five-year survival of